Attenuation of immune-mediated influenza pneumonia by targeting the inducible co-stimulator (ICOS) molecule on T cells

PLoS One. 2014 Jul 16;9(7):e100970. doi: 10.1371/journal.pone.0100970. eCollection 2014.

Abstract

Inducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key player in balancing T effector and T regulatory (Treg) cell responses. Here we show that activation of the ICOS signalling pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency of CD8+ T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4+Foxp3+ Tregs in IAV infected mice, which was associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings suggest a prominent role of ICOS signaling during acute IAV infection by increasing the Treg/CD8+ T cell ratio with beneficial outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated cytopathic effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / drug effects*
  • CD8-Positive T-Lymphocytes / immunology*
  • Female
  • Humans
  • Inducible T-Cell Co-Stimulator Protein / agonists
  • Inducible T-Cell Co-Stimulator Protein / metabolism*
  • Interleukin-10 / metabolism
  • Lung / drug effects
  • Lung / immunology
  • Lung / microbiology
  • Lung / virology
  • Mice
  • Molecular Targeted Therapy / methods*
  • Orthomyxoviridae Infections / complications*
  • Pneumonia / complications
  • Pneumonia / drug therapy*
  • Pneumonia / immunology*
  • Pneumonia / metabolism

Substances

  • Inducible T-Cell Co-Stimulator Protein
  • Interleukin-10

Grants and funding

This study was funded by the Alexander-von-Humboldt Foundation providing a postdoctoral fellowship to Priya Sakthivel. Dunja Bruder received financial support from the President’s Initiative and Networking Fund of the Helmholtz Association of German Research Centers (HGF) under contract number W2/W3-029 and from the Centre of Dynamic Systems (CDS), Magdeburg. Umberto Dianzani and Luca Gigliotti received financial support from the Associazione Italiana Ricerca sul Cancro (Milano) and Fondazione Amici di Jean (Torino). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.